黑料吃瓜群网

TGA fast-tracks approval of COVID-19-busting disinfectants


Saturday, 28 March, 2020

TGA fast-tracks approval of COVID-19-busting disinfectants

The (TGA) has identified disinfectants as critical in preventing the spread of COVID-19 and as such is fast-tracking disinfectant applications in relation to claims against COVID-19.

The TGA has published amendments to the (TGO 104) to allow listed disinfectants to make validated claims to kill the COVID-19 virus on surfaces. Disinfectants that claim to kill microorganisms 鈥 including COVID-19 鈥 must comply with the Therapeutic Goods (Standard for Disinfectants and Sanitary Products) (TGO 104) Order 2019 and the .

According to the TGA, 鈥淐OVID-19 is an enveloped virus, which means it has an outer membrane. Enveloped viruses are relatively easy to kill compared to non-enveloped viruses, as the outer layer is easily damaged by most environmental disinfectants, provided the disinfectant is used in accordance with label directions.

鈥淒isinfectants containing 鈮70% alcohol, quaternary ammonium or diluted household bleach are suitable for use.鈥

Chairman Dr Greg Whiteley said, 鈥淭his is a great example of collaboration in a time of national and international crisis with the COVID-19 pandemic.

鈥淭he TGA worked with industry association Australasia to negotiate a pragmatic approach that will assist in alleviating public health concerns over the risk of the spread of the virus via hospital and medical surfaces.

鈥淭he TGA and ACCORD leadership are to be congratulated on the speedy outcome of this change process which will benefit all of the Australian medical community and the medical manufacturing sector. This new technical arrangement will allow improved certainty around disinfecting surfaces within healthcare settings,鈥 Dr Whiteley said.

The TGA states that sponsors and manufacturers of hard-surface disinfectants 鈥 or disinfectants that are medical devices 鈥 wishing to make label claims of efficacy against COVID-19 must demonstrate efficacy against the surrogate virus human coronavirus 229E or murine hepatitis virus. Consideration can also be given to products that kill other human or animal coronaviruses.

鈥淲e would like to note particular thanks to Adjunct Professor John Skerritt and the entire team inside the TGA, and also to Bronwyn Capanna, Executive Director of ACCORD Australasia and her team at ACCORD, for achieving this outcome鈥 Dr Whiteley said.

鈥淭here are continuing negotiations on further improvements around other vital infection-prevention technologies. This collaborative process allows Australians to have increased levels of certainty around the health and hygiene standards within Australian hospitals and healthcare providers.

Image credit: 漏stock.adobe.com/au/alenaohneva

Related News

Victoria's Q3 median ED wait times the lowest on record

Victoria's quarter three performance data (January–March) has shown improvement across...

Irregularities in a clinician's cases prompt 15-month lookback

St Vincent's 黑料吃瓜群网 Sydney has detailed a 15-month lookback review — prompted by...

Two researchers receive $899,000 in cardiovascular funding

In heart-related news this Heart Week (5–11 May), two University of Newcastle researchers...



Content from other channels on our network


  • All content Copyright 漏 2025 黑料吃瓜群网-Farrow Pty Ltd